Prognostic Significance of Substance P and Neurokinin-1 Receptor in Bladder Cancer

Bladder cancer is one of the most common genitourinary cancers with significant mortality. Finding reliable tumor markers and potential drug targets can improve early diagnosis, prognosis, and more effective therapeutic protocols. Previous studies have reported the involvement of the substance P (SP...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Reports of biochemistry and molecular biology 2022-10, Vol.11 (3), p.411-420
Hauptverfasser: Zahiri, Elnaz, Ghorbani, Hamidreza, Moradi, Ali, Mehrad-Majd, Hassan, Mohammadi, Fariba, Sharifi Sistani, Noorieh, Hashemy, Seyed Isaac
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 420
container_issue 3
container_start_page 411
container_title Reports of biochemistry and molecular biology
container_volume 11
creator Zahiri, Elnaz
Ghorbani, Hamidreza
Moradi, Ali
Mehrad-Majd, Hassan
Mohammadi, Fariba
Sharifi Sistani, Noorieh
Hashemy, Seyed Isaac
description Bladder cancer is one of the most common genitourinary cancers with significant mortality. Finding reliable tumor markers and potential drug targets can improve early diagnosis, prognosis, and more effective therapeutic protocols. Previous studies have reported the involvement of the substance P (SP)/neurokinin-1 receptor (NK-1R) system in cancers. The potential prognostic role and the interaction of SP and NK-1R in bladder tumor are yet to be elucidated. Serum samples from 22 primarily diagnosed patients with bladder cancer as well as 22 healthy controls were examined for SP level using ELISA method. Tissue distribution of NK-1R in tumor samples and their adjacent normal tissues was evaluated through immunohistochemistry. Serum SP levels in patients with bladder cancer were higher than the healthy group (p< 0.001) and had a significant correlation with NK-1R staining intensity (p< 0.001), percentage of stained cells (p< 0.001), and NK-1R tissue distribution. Also, the immunoreactivity of NK-1R in cancer samples increased significantly without correlation with tumor characteristics. However, no significant association was found between SP and NK-1R levels with clinical characteristics including tumor size (p= 0.33), tumor stage (p= 0.29), grade (p= 0.93), NK-1R staining intensity (p= 0.53), and percentage of stained cells (p= 0.32). According to our findings, despite the lack of association between SP and NK-1R with clinical characteristics of bladder cancer, their serum levels were higher in patients with bladder cancer. Further studies are needed to confirm the potential prognostic role of SP and NK-1R in bladder cancer.
doi_str_mv 10.52547/rbmb.11.3.411
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9883027</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2771331760</sourcerecordid><originalsourceid>FETCH-LOGICAL-c275t-793add5b4195e372c87909b73d7550057f55e9551920e66b4e2e68e6492207cf3</originalsourceid><addsrcrecordid>eNpVkctLxDAQxoMoruhePUqOXlrzaJLmIujiC0TFxzm06XSNdpM1aQX_e-uuip5mhvnNN8N8CO1TkgsmCnUU60WdU5rzvKB0A-0wzljGi5Js_sknaJrSCyGEMiGllttowqWiJdN8B93fxTD3IfXO4gc39651tvIWcGjxw1CnflXc4co3-AaGGF6ddz6j-B4sLPsQsfP4tKuaBiKefcFxD221VZdg-h130dP52ePsMru-vbianVxnlinRZ0rzcUrUBdUCuGK2VJroWvFGCUGIUK0QoIWgmhGQsi6AgSxBFpoxomzLd9HxWnc51AtoLPg-Vp1ZRreo4ocJlTP_O949m3l4N7osOWFqFDj8FojhbYDUm4VLFrqu8hCGZJhSlHOqJBnRfI3aGFKK0P6uocSsvDBfXhhKDTejF-PAwd_jfvGfz_NPk8KEuA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2771331760</pqid></control><display><type>article</type><title>Prognostic Significance of Substance P and Neurokinin-1 Receptor in Bladder Cancer</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Zahiri, Elnaz ; Ghorbani, Hamidreza ; Moradi, Ali ; Mehrad-Majd, Hassan ; Mohammadi, Fariba ; Sharifi Sistani, Noorieh ; Hashemy, Seyed Isaac</creator><creatorcontrib>Zahiri, Elnaz ; Ghorbani, Hamidreza ; Moradi, Ali ; Mehrad-Majd, Hassan ; Mohammadi, Fariba ; Sharifi Sistani, Noorieh ; Hashemy, Seyed Isaac ; Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran &amp; Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran ; Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran ; Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran ; Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran &amp; Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran ; Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran ; Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran ; Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran &amp; Orthopedic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><description>Bladder cancer is one of the most common genitourinary cancers with significant mortality. Finding reliable tumor markers and potential drug targets can improve early diagnosis, prognosis, and more effective therapeutic protocols. Previous studies have reported the involvement of the substance P (SP)/neurokinin-1 receptor (NK-1R) system in cancers. The potential prognostic role and the interaction of SP and NK-1R in bladder tumor are yet to be elucidated. Serum samples from 22 primarily diagnosed patients with bladder cancer as well as 22 healthy controls were examined for SP level using ELISA method. Tissue distribution of NK-1R in tumor samples and their adjacent normal tissues was evaluated through immunohistochemistry. Serum SP levels in patients with bladder cancer were higher than the healthy group (p&lt; 0.001) and had a significant correlation with NK-1R staining intensity (p&lt; 0.001), percentage of stained cells (p&lt; 0.001), and NK-1R tissue distribution. Also, the immunoreactivity of NK-1R in cancer samples increased significantly without correlation with tumor characteristics. However, no significant association was found between SP and NK-1R levels with clinical characteristics including tumor size (p= 0.33), tumor stage (p= 0.29), grade (p= 0.93), NK-1R staining intensity (p= 0.53), and percentage of stained cells (p= 0.32). According to our findings, despite the lack of association between SP and NK-1R with clinical characteristics of bladder cancer, their serum levels were higher in patients with bladder cancer. Further studies are needed to confirm the potential prognostic role of SP and NK-1R in bladder cancer.</description><identifier>ISSN: 2322-3480</identifier><identifier>EISSN: 2322-3480</identifier><identifier>DOI: 10.52547/rbmb.11.3.411</identifier><identifier>PMID: 36718293</identifier><language>eng</language><publisher>Iran: Varastegan Institute for Medical Sciences</publisher><subject>Original</subject><ispartof>Reports of biochemistry and molecular biology, 2022-10, Vol.11 (3), p.411-420</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c275t-793add5b4195e372c87909b73d7550057f55e9551920e66b4e2e68e6492207cf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883027/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883027/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36718293$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zahiri, Elnaz</creatorcontrib><creatorcontrib>Ghorbani, Hamidreza</creatorcontrib><creatorcontrib>Moradi, Ali</creatorcontrib><creatorcontrib>Mehrad-Majd, Hassan</creatorcontrib><creatorcontrib>Mohammadi, Fariba</creatorcontrib><creatorcontrib>Sharifi Sistani, Noorieh</creatorcontrib><creatorcontrib>Hashemy, Seyed Isaac</creatorcontrib><creatorcontrib>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran &amp; Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><creatorcontrib>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><creatorcontrib>Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><creatorcontrib>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran &amp; Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><creatorcontrib>Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><creatorcontrib>Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><creatorcontrib>Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran &amp; Orthopedic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><title>Prognostic Significance of Substance P and Neurokinin-1 Receptor in Bladder Cancer</title><title>Reports of biochemistry and molecular biology</title><addtitle>Rep Biochem Mol Biol</addtitle><description>Bladder cancer is one of the most common genitourinary cancers with significant mortality. Finding reliable tumor markers and potential drug targets can improve early diagnosis, prognosis, and more effective therapeutic protocols. Previous studies have reported the involvement of the substance P (SP)/neurokinin-1 receptor (NK-1R) system in cancers. The potential prognostic role and the interaction of SP and NK-1R in bladder tumor are yet to be elucidated. Serum samples from 22 primarily diagnosed patients with bladder cancer as well as 22 healthy controls were examined for SP level using ELISA method. Tissue distribution of NK-1R in tumor samples and their adjacent normal tissues was evaluated through immunohistochemistry. Serum SP levels in patients with bladder cancer were higher than the healthy group (p&lt; 0.001) and had a significant correlation with NK-1R staining intensity (p&lt; 0.001), percentage of stained cells (p&lt; 0.001), and NK-1R tissue distribution. Also, the immunoreactivity of NK-1R in cancer samples increased significantly without correlation with tumor characteristics. However, no significant association was found between SP and NK-1R levels with clinical characteristics including tumor size (p= 0.33), tumor stage (p= 0.29), grade (p= 0.93), NK-1R staining intensity (p= 0.53), and percentage of stained cells (p= 0.32). According to our findings, despite the lack of association between SP and NK-1R with clinical characteristics of bladder cancer, their serum levels were higher in patients with bladder cancer. Further studies are needed to confirm the potential prognostic role of SP and NK-1R in bladder cancer.</description><subject>Original</subject><issn>2322-3480</issn><issn>2322-3480</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkctLxDAQxoMoruhePUqOXlrzaJLmIujiC0TFxzm06XSNdpM1aQX_e-uuip5mhvnNN8N8CO1TkgsmCnUU60WdU5rzvKB0A-0wzljGi5Js_sknaJrSCyGEMiGllttowqWiJdN8B93fxTD3IfXO4gc39651tvIWcGjxw1CnflXc4co3-AaGGF6ddz6j-B4sLPsQsfP4tKuaBiKefcFxD221VZdg-h130dP52ePsMru-vbianVxnlinRZ0rzcUrUBdUCuGK2VJroWvFGCUGIUK0QoIWgmhGQsi6AgSxBFpoxomzLd9HxWnc51AtoLPg-Vp1ZRreo4ocJlTP_O949m3l4N7osOWFqFDj8FojhbYDUm4VLFrqu8hCGZJhSlHOqJBnRfI3aGFKK0P6uocSsvDBfXhhKDTejF-PAwd_jfvGfz_NPk8KEuA</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Zahiri, Elnaz</creator><creator>Ghorbani, Hamidreza</creator><creator>Moradi, Ali</creator><creator>Mehrad-Majd, Hassan</creator><creator>Mohammadi, Fariba</creator><creator>Sharifi Sistani, Noorieh</creator><creator>Hashemy, Seyed Isaac</creator><general>Varastegan Institute for Medical Sciences</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221001</creationdate><title>Prognostic Significance of Substance P and Neurokinin-1 Receptor in Bladder Cancer</title><author>Zahiri, Elnaz ; Ghorbani, Hamidreza ; Moradi, Ali ; Mehrad-Majd, Hassan ; Mohammadi, Fariba ; Sharifi Sistani, Noorieh ; Hashemy, Seyed Isaac</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c275t-793add5b4195e372c87909b73d7550057f55e9551920e66b4e2e68e6492207cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Zahiri, Elnaz</creatorcontrib><creatorcontrib>Ghorbani, Hamidreza</creatorcontrib><creatorcontrib>Moradi, Ali</creatorcontrib><creatorcontrib>Mehrad-Majd, Hassan</creatorcontrib><creatorcontrib>Mohammadi, Fariba</creatorcontrib><creatorcontrib>Sharifi Sistani, Noorieh</creatorcontrib><creatorcontrib>Hashemy, Seyed Isaac</creatorcontrib><creatorcontrib>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran &amp; Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><creatorcontrib>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><creatorcontrib>Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><creatorcontrib>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran &amp; Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><creatorcontrib>Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><creatorcontrib>Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><creatorcontrib>Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran &amp; Orthopedic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Reports of biochemistry and molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zahiri, Elnaz</au><au>Ghorbani, Hamidreza</au><au>Moradi, Ali</au><au>Mehrad-Majd, Hassan</au><au>Mohammadi, Fariba</au><au>Sharifi Sistani, Noorieh</au><au>Hashemy, Seyed Isaac</au><aucorp>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran &amp; Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran</aucorp><aucorp>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</aucorp><aucorp>Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</aucorp><aucorp>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran &amp; Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</aucorp><aucorp>Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</aucorp><aucorp>Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran</aucorp><aucorp>Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran &amp; Orthopedic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Significance of Substance P and Neurokinin-1 Receptor in Bladder Cancer</atitle><jtitle>Reports of biochemistry and molecular biology</jtitle><addtitle>Rep Biochem Mol Biol</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>11</volume><issue>3</issue><spage>411</spage><epage>420</epage><pages>411-420</pages><issn>2322-3480</issn><eissn>2322-3480</eissn><abstract>Bladder cancer is one of the most common genitourinary cancers with significant mortality. Finding reliable tumor markers and potential drug targets can improve early diagnosis, prognosis, and more effective therapeutic protocols. Previous studies have reported the involvement of the substance P (SP)/neurokinin-1 receptor (NK-1R) system in cancers. The potential prognostic role and the interaction of SP and NK-1R in bladder tumor are yet to be elucidated. Serum samples from 22 primarily diagnosed patients with bladder cancer as well as 22 healthy controls were examined for SP level using ELISA method. Tissue distribution of NK-1R in tumor samples and their adjacent normal tissues was evaluated through immunohistochemistry. Serum SP levels in patients with bladder cancer were higher than the healthy group (p&lt; 0.001) and had a significant correlation with NK-1R staining intensity (p&lt; 0.001), percentage of stained cells (p&lt; 0.001), and NK-1R tissue distribution. Also, the immunoreactivity of NK-1R in cancer samples increased significantly without correlation with tumor characteristics. However, no significant association was found between SP and NK-1R levels with clinical characteristics including tumor size (p= 0.33), tumor stage (p= 0.29), grade (p= 0.93), NK-1R staining intensity (p= 0.53), and percentage of stained cells (p= 0.32). According to our findings, despite the lack of association between SP and NK-1R with clinical characteristics of bladder cancer, their serum levels were higher in patients with bladder cancer. Further studies are needed to confirm the potential prognostic role of SP and NK-1R in bladder cancer.</abstract><cop>Iran</cop><pub>Varastegan Institute for Medical Sciences</pub><pmid>36718293</pmid><doi>10.52547/rbmb.11.3.411</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2322-3480
ispartof Reports of biochemistry and molecular biology, 2022-10, Vol.11 (3), p.411-420
issn 2322-3480
2322-3480
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9883027
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Original
title Prognostic Significance of Substance P and Neurokinin-1 Receptor in Bladder Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T12%3A09%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Significance%20of%20Substance%20P%20and%20Neurokinin-1%20Receptor%20in%20Bladder%20Cancer&rft.jtitle=Reports%20of%20biochemistry%20and%20molecular%20biology&rft.au=Zahiri,%20Elnaz&rft.aucorp=Department%20of%20Clinical%20Biochemistry,%20Faculty%20of%20Medicine,%20Mashhad%20University%20of%20Medical%20Sciences,%20Mashhad,%20Iran%20&%20Clinical%20Research%20Development%20Unit,%20Ghaem%20Hospital,%20Mashhad%20University%20of%20Medical%20Sciences,%20Mashhad,%20Iran&rft.date=2022-10-01&rft.volume=11&rft.issue=3&rft.spage=411&rft.epage=420&rft.pages=411-420&rft.issn=2322-3480&rft.eissn=2322-3480&rft_id=info:doi/10.52547/rbmb.11.3.411&rft_dat=%3Cproquest_pubme%3E2771331760%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2771331760&rft_id=info:pmid/36718293&rfr_iscdi=true